Here are 2 blue chip ASX 200 shares to add to your portfolio: brokers

The Australian share market certainly is not short of blue chip options. But which ones should you buy?

To help narrow things down, listed below are two top blue chip ASX 200 shares that are rated as buys by experts. Here’s what you need to know about them:

CSL Limited (ASX: CSL)

The first blue chip ASX 200 share to consider is CSL. It is one of the world’s leading biotechnology companies and the name behind the CSL Behring, CSL Vifor, and Seqirus businesses.

The CSL Vifor business is a recent addition following a blockbuster acquisition earlier this year. As a global specialty pharmaceutical leader, it adds iron deficiency, nephrology (kidney care), and cardio-renal therapies to CSL’s world class product portfolio.

And thanks to the company’s investment of around 10% of sales into research and development activities each year, CSL has a pipeline of potentially lucrative and lifesaving therapies coming to market in the next few years if approved by regulators.

Citi is positive on CSL and currently has a buy rating and $340.00 price target on its shares.

National Australia Bank Ltd (ASX: NAB)

Another blue chip ASX 200 share that could be a good option right now for investors is this banking giant.

NAB appears well-placed to profit in the current environment with rates rising and its overweight exposure to commercial lending.

It is because of the latter that Goldman Sachs is positive on the bank. It sees “volume momentum over the next 12 months as favouring commercial volumes over housing volumes and NAB provides the best exposure to this thematic.”

The broker currently has a buy rating and $35.15 price target on the bank’s shares. It also expects a ~5% fully franked dividend yield in FY 2023.

The post Here are 2 blue chip ASX 200 shares to add to your portfolio: brokers appeared first on The Motley Fool Australia.

More reading

• The ASX shares I’d buy now to put away for 4 years: advisor
• If I’d invested $5,000 in these 5 ASX shares five years ago, here’s what I’d have now
• What’s the outlook for ASX healthcare shares in Q2?
• NAB share price lifts amid ‘first for a major Australian bank’
• CSL shares ‘still not fully appreciated’: Wilsons

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/4ARwVYl